IL6ST and pancreatic neoplasm: The median overall survival for PDAC patients with no epithelial gp130 expression was 15.9 (IQR 10.7–30.0) months, whereas for patients expressing epithelial gp130 in the pancreatic tumors was 16.7 (IQR 8.5–37.7) months (p = 0.830).